Restoration of Mitochondrial Cardiolipin Attenuates Cardiac Damage in Swine Renovascular Hypertension by Eirin, Alfonso et al.
Henry Ford Health System 
Henry Ford Health System Scholarly Commons 
Cardiology Articles Cardiology/Cardiovascular Research 
5-31-2016 
Restoration of Mitochondrial Cardiolipin Attenuates Cardiac 
Damage in Swine Renovascular Hypertension. 
Alfonso Eirin 
Behzad Ebrahimi 
Soon Hyo Kwon 
Justin A. Fiala 
Barbara J. Williams 
See next page for additional authors 
Follow this and additional works at: https://scholarlycommons.henryford.com/cardiology_articles 
Recommended Citation 
Eirin A, Ebrahimi B, Kwon SH, Fiala JA, Williams BJ, Woollard JR, He Q, Gupta RC, Sabbah HN, Prakash YS, 
Textor SC, Lerman A, Lerman LO. Restoration of mitochondrial cardiolipin attenuates cardiac damage in 
swine renovascular hypertension. J Am Heart Assoc. 2016;5(6) 
This Article is brought to you for free and open access by the Cardiology/Cardiovascular Research at Henry Ford 
Health System Scholarly Commons. It has been accepted for inclusion in Cardiology Articles by an authorized 
administrator of Henry Ford Health System Scholarly Commons. 
Authors 
Alfonso Eirin, Behzad Ebrahimi, Soon Hyo Kwon, Justin A. Fiala, Barbara J. Williams, John R. Woollard, 
Quan He, Ramesh C. Gupta, Hani N. Sabbah, Y S. Prakash, Stephen C. Textor, Amir Lerman, and Lilach O. 
Lerman 
This article is available at Henry Ford Health System Scholarly Commons: https://scholarlycommons.henryford.com/
cardiology_articles/283 
Restoration of Mitochondrial Cardiolipin Attenuates Cardiac Damage
in Swine Renovascular Hypertension
Alfonso Eirin, MD; Behzad Ebrahimi, PhD; Soon Hyo Kwon, MD; Justin A. Fiala, MD; Barbara J. Williams, BS; John R. Woollard, MS;
Quan He, PhD; Ramech C. Gupta, PhD; Hani N. Sabbah, PhD; Y.S. Prakash, MD, PhD; Stephen C. Textor, MD; Amir Lerman, MD;
Lilach O. Lerman, MD, PhD
Background-—Renovascular hypertension (RVH) impairs cardiac structure and left ventricular (LV) function, but whether
mitochondrial injury is implicated in RVH-induced myocardial damage and dysfunction has not been defined. We hypothesized that
cardiac remodeling in swine RVH is partly attributable to cardiac mitochondrial injury.
Methods and Results-—After 12 weeks of hypercholesterolemic (HC)-RVH or control (n=14 each), pigs were treated for another
4 weeks with vehicle or with the mitochondrial-targeted peptide (MTP), Bendavia (0.1 mg/kg subcutaneously, 5 days/week),
which stabilizes mitochondrial inner-membrane cardiolipin (n=7 each). Cardiac function was subsequently assessed by
multidetector-computed tomography and oxygenation by blood-oxygen-level–dependent magnetic resonance imaging. Cardiolipin
content, mitochondrial biogenesis, as well as sarcoplasmic-reticulum calcium cycling, myocardial tissue injury, and coronary
endothelial function were assessed ex vivo. Additionally, mitochondrial cardiolipin content, oxidative stress, and bioenergetics were
assessed in rat cardiomyocytes incubated with tert-butyl hydroperoxide (tBHP) untreated or treated with MTP. Chronic
mitoprotection in vivo restored cardiolipin content and mitochondrial biogenesis. Thapsigargin-sensitive sarcoplasmic reticulum
Ca2+-ATPase activity that declined in HC-RVH normalized in MTP-treated pigs. Mitoprotection also improved LV relaxation (E/A
ratio) and ameliorated cardiac hypertrophy, without affecting blood pressure or systolic function. Myocardial remodeling and
coronary endothelial function improved only in MTP-treated pigs. In tBHP-treated cardiomyocytes, mitochondrial targeting
attenuated a fall in cardiolipin content and bioenergetics.
Conclusions-—Chronic mitoprotection blunted myocardial hypertrophy, improved LV relaxation, and attenuated myocardial cellular
and microvascular remodeling, despite sustained HC-RVH, suggesting that mitochondrial injury partly contributes to hypertensive
cardiomyopathy. ( J Am Heart Assoc. 2016;5:e003118 doi: 10.1161/JAHA.115.003118)
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R enovascular hypertension (RVH) accompanied by kid-ney dysfunction is prevalent in elderly individuals and
commonly associated with cardiac abnormalities and dys-
function.1 Importantly, patients with RVH also have
increased mortality rate, warranting development of
preventive and management strategies for these patients.2
We have previously shown that left ventricular (LV) structure
and relaxation are selectively impaired in RVH compared
with essential hypertensive patients.3 Alas, to date, few
treatment options are available to improve cardiac structure
and dysfunction in hypertension, possibly because of the
lack of clinically applicable therapies targeting underlying
biological mechanisms.
Accumulating evidence suggests that mitochondrial abnor-
malities and dysfunction are important contributors to
hypertension-induced damage in the heart and other major
target organs.4,5 For example, murine mitochondrial DNA
mutations induce cardiac hypertrophy and dilatation, partly
mediated by mitochondrial dysfunction and apoptosis.6
Cardiac mitochondria regulate calcium homeostasis, by
capturing and recycling released calcium.7 However, in failing
cardiomyocytes, mitochondrial calcium overload triggers
opening of the mitochondrial permeability-transition-pore
(mPTP), resulting in mitochondrial swelling and release of
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cytochrome-c to the cytosol and reactive oxygen species
(ROS), leading to apoptosis and oxidative stress. In agree-
ment, we have previously shown that experimental RVH
induces myocardial apoptosis, oxidative stress, fibrosis, LV
remodeling, and dysfunction, associated with decreased
mitochondrial biogenesis,8 underscoring a potential physio-
logical role for mitochondria in cardiomyocyte homeostasis.
Mitochondria also regulate cardiac endothelial cell function
through modulating intracellular concentrations of ROS, nitric
oxide (NO), and calcium. For example, endothelial NO
synthesis depends on the activity of the mitochondrial
enzyme arginase-II,9 whereas uncoupling protein (UCP)-2, an
inner mitochondrial membrane transporter, preserves
endothelial function by preventing mitochondrial ROS-induced
NO deficiency.10 Excessive mitochondrial ROS contributes to
impaired coronary vascular relaxation, triggering oxidative
damage and mitochondrial dysfunction.11 When mitochondrial
function is affected, endothelial cell migration, tube formation,
and angiogenesis are compromised, resulting in microvascular
remodeling and loss.12 Damage to the cardiovascular
endothelium is a major risk factor for heart disease, thus
strategies aimed to protect both cardiomyocyte and endothe-
lial cell mitochondria may attenuate RVH-induced myocardial
remodeling and dysfunction.
Cardiolipin13 is a phospholipid found only in the inner
mitochondrial membrane.14 Its unique conical structure, which
imparts properties favoring membrane curvature, makes car-
diolipin ideal for forming cristae and supercomplexes in the
electronic transport chain and maintaining mitochondrial
bioenergetics.15 Furthermore, cardiolipin anchors cyto-
chrome-c to the inner mitochondrial membrane, facilitating
electron transfer between complexes III and IV.16 However,
cardiolipin is vulnerable to increased cytosolic calcium and
oxidative stress, which invoke its peroxidation and subsequent
loss,17 leading to mitochondrial dysfunction underpinning
various forms of cardiovascular disease.
Experimental studies have shown that cardiolipin protec-
tion adjunctive to reperfusion injury limits myocardial infarct
size and improves cardiac function,18 implicating mitochon-
drial damage in acute cardiac insults. The mitochondria-
targeted peptide (MTP), Bendavia, targets the mitochondrial
matrix independent of membrane potential, preventing per-
oxidation of cardiolipin.13 We have also previously shown that
a single 3-hour MTP infusion during swine renal revascular-
ization that led to regression of hypertension expedited
subsequent cardiac recovery.8 Yet, the ability to blunt
hypertension-induced cardiomyopathy by mitoprotection in
the face of ongoing hypertension remained unknown. There-
fore, the current study tested the hypothesis that mitochon-
drial injury mediates RVH-induced cardiac damage, and that
chronic mitoprotection can decrease cardiac remodeling and
improve its function in hypertensive pigs.
Methods
Study Groups and Experimental Design
Animal procedures were approved by the Institutional Animal
care and Use Committee. Female domestic pigs (n=28) were
studied after 16 weeks of observation (Figure 1A).
At baseline, pigs were randomized as hypercholecterolemic
(HC)-RVH or normal controls (n=14 each). To simulate
concurrent atherosclerosis, HC-RVH pigs started a high-
cholesterol diet (2% cholesterol and 15% lard (TD-93296;
Harlan-Teklad, Madison, WI),19 whereas normal pigs con-
sumed standard pig chow.
Six weeks later, renal artery stenosis and RVH were induced
in pigs by placing a local-irritant coil in the main renal artery,
which increases arterial pressure within 7 to 10 days,20
whereas normal pigs underwent a sham procedure. Anesthesia
was induced with 0.25 g of intramuscular tiletamine hydrochlo-
ride/zolazepam hydrochloride and 0.5 g of xylazine, and
maintained with intravenous ketamine (0.2 mg/kg per minute)
and xylazine (0.03 mg/kg per minute).
Six weeks after induction of RVH, animals were similarly
anesthetized. Daily subcutaneous injections of the MTP
Bendavia (Stealth BioTherapeutics, Inc. Newton, MA; 0.1 mg/
kg in 1 mL of PBS, 1/day 5 days/week) or vehicle (PBS) were
then initiated in both HC-RVH and sham pigs (n=7 each group).
Four weeks later, the degree of stenosis was determined
by angiography and systemic venous blood samples collected
under similar anesthesia. Creatinine, plasma renin activity
(PRA), cholesterol fractions and triglycerides levels were
measured.8,21 Multidetector computed tomography (MDCT)
and blood oxygen-level–dependent magnetic-resonance imag-
ing (BOLD-MRI) scanning was conducted to assess cardiac
function and myocardial oxygenation, respectively.
A few days after completion of in vivo studies, pigs were
euthanized (intravenous sodium pentobarbital, 100 mg/kg,
Fatal Plus; Vortech Pharmaceuticals, Dearborn, MI). LV tissue
was harvested, frozen in liquid nitrogen (and maintained at
80°C), or preserved in formalin for ex vivo studies. Another
segment was prepared for micro-CT studies. Additionally,
main branches of the coronary artery were dissected and
placed in control solution for in vitro assessment of coronary
endothelial function.
Cardiac Oxygenation and Function
BOLD-MRI was performed to assess myocardial oxygenation,
as we described.22 Briefly, pigs anesthetized with 1% to 2%
isoflurane were positioned in the MRI scanner (3 Tesla, Signa
Echo Speed; GE Medical Systems, Milwaukee, WI). Scans were
performed during suspended respiration before and after a 5-
minute intravenous injection of adenosine (400 lg/kg per
minute). The average relaxivity index R2*, a surrogate of
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myocardial hypoxia, was estimated in regions of interest traced
in the septum in each slice, and images analyzed using MATLAB
software (version 7.10; The MathWorks, Inc., Natick, MA).22
Two days after BOLD-MRI studies, 64-slice MDCT (Soma-
tom Definition-64; Siemens Medical Solution, Forchheim,
Germany) studies were performed before and during a
5-minute intravenous infusion of adenosine (400 lg/kg per
minute). The entire LV was scanned throughout the cardiac
cycle to obtain cardiac systolic function, end-diastolic volume
(EDV), and LV muscle mass (LVMM).23 Early (E) and late (A) LV
filling rates were obtained from the volume/time curve, and
myocardial perfusion from time-attenuation curves obtained
from the anterior cardiac wall, as described.24 Images were
analyzed with the Analyze software package (Biomedical
Imaging Resource; Mayo Clinic, Rochester, MN).
Myocardial Injury and Remodeling
Myocardial apoptosis was evaluated in LV sections double
stained with terminal deoxynucleotidyl transferase-mediated
dUTP nick end end-labeling (TUNEL; Promega, Madison, WI)
and connexin-43 (Catalog No.: ab79010; Abcam, Cambridge,
MA) fluorescent staining.8 Protein expression of the anti-
apoptotic, B-cell lymphoma (Bcl)-xl (1:1000; Lifespan BioS-
ciences, Seattle, WA), was assessed by Western blotting.19 In
situ production of superoxide anion was detected using
dihydroethidium (DHE),21 and myocardial expression of the
NAD(P)H-oxidase subunit p47 and gp91 by Wester -blotting
(both 1:200; Santa Cruz Biotechnology, Santa Cruz, CA).8
Additionally, total ROS burden was determined in LV samples.
In brief, 50 mg of LV tissue were homogenized by polytron
in 1 mL of PBS buffer and centrifuged at 16 099 g for
10 minutes. Clear supernatant was collected and protein
determined by Bio-Rad DC Protein Assay (Bio-Rad Laborato-
ries, Hercules, CA). A 100-lL aliquot of the diluted samples in
PBS was added into a 96-well plate followed by 100 lL of
SuperSignal West Pico Luminol solution (1 part of Luminol,
Product No. 1856136+1 part of Stable Peroxide Solution,
Product No. 1856135; Thermo Scientific, Waltham, MA). After
the resulting mixture was incubated for 5 minutes at room
Figure 1. Mitochondrial-targeted peptides (MTP) improved myocardial oxygenation. A, Schematic of the
experimental protocol. B, Representative left ventricular cross-sectional images of blood-oxygen-level–
dependent magnetic resonance imaging (BOLD-MRI), showing hypoxic myocardium (red) before and after
adenosine (top). Quantification of R2* signal (bottom). *P<0.05 vs Normal+Vehicle; #P<0.05 vs
Normal+MTP; †P<0.05 vs hypercholesterolemic renovascular hypertension (HC-RVH)+MTP; ‡P<0.05 vs
baseline. HC indicates hypercholesterolemic; RVH, renovascular hypertension; SC, subcutaneous.
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temperature, luminescence reading was taken by a Tecan
Saffire (Tecan Group Ltd., M€annedorf, Switzerland). Values are
expressed as relative luminescence units (RLU)/mg protein.
Thapsigargin-sensitive sarcoplasmic reticulum (SR) Ca2+-
ATPase (SERCA-2a) activity in membrane vesicles was
determined at free Ca2+ concentrations ranging from 0.1 to
10 lmol/L in a total assay volume of 200 lL, as described
previously.25,26 Briefly, 200 mg of LV powder were homog-
enized in the presence of protease and phosphatase inhibitors
(Sigma-Aldrich, St. Louis, MO), membrane vesicles isolated
from the LV homogenate, and protein determined using the
Bio-Rad DC Protein Assay (Bio-Rad Laboratories). SERCA-2a
activity was determined in the absence and presence of
1 lmol/L of thapsigargin. In parallel, known concentrations
of Pi between 0.1 and 0.5 lmol were run as standard for
calculating the amount of Pi released during the enzyme
reaction. The difference between the activities assayed in the
presence and absence of thapsigargin was considered as the
activity of SERCA-2a associated with the SR. Maximal velocity
(Vmax) of SERCA-2a activity expressed as nmol Pi released/
minutes per mg and affinity (K0.5) expressed as lmol/L were
calculated.
Protein level of SERCA-2a (Thermo Scientific), phosphory-
lated phospholamban (PLB) at serine 16 (pPLB-S16; Badrilla
Ltd., Leeds, UK), total PLB (t-PLB; Badrilla), total ryanodine
receptor (RyR2; Abcam), phosphorylated RyR2 at serine 2808
(p-RyR2-S2808; Abcam), and sodium-calcium exchanger
(NCX; Thermo scientific) in LV homogenate was measured
by Western blotting. Briefly, LV homogenate was prepared
from 100 mg LV powder as described previously,27,28 and
protein level was determined by Bio-Rad DC Protein Assay
(Bio-Rad Laboratories). Approximately 10 to 100 lg of protein
of each dog LV sample was separated on 4% to 20% SDS-
polyacrylamide gel (Bio-Rad Laboratories), and the separated
proteins were electrophoretically transferred to a PVDF
membrane. Accuracy of the electrotransfer was confirmed
by staining the membrane with 0.1% Panacea S dye. For
identification of the desired protein, the blot was incubated
with the appropriately diluted primary monoclonal or poly-
clonal antibody specific to each protein, based on the
supplier’s instructions. Antibody-binding protein(s) was visual-
ized by autoradiography after treating the blot with HRP-
conjugated secondary antibody (antirabbit) and enhanced
chemiluminescence color developing reagents according to
the supplier (Thermo Scientific). Band intensity was quantified
using a Bio-Rad GS-670 imaging densitometer (Bio-Rad Labo-
ratories). Calsequestrin, a calcium-binding protein of the SR
whose levels remain unaltered during heart failure,25,29 was
used as a control for normalization of all proteins. In all cases,
the antibody was in excess over the antigen and the density of
each protein band was in the linear scale. Furthermore,
immunofluorescence costaining of the mitochondrial
membrane through a voltage-dependent anion channel (VDAC)
and the sarcoplasmic-reticulum marker, RYR, was performed
and colocalization assessed with theMander’s coefficient using
the National Institutes of Health ImageJ software (version 1.44
for Windows) and the Colocalization Plugin,30 and reported as
M1 (overlap between VDAC and RyR).31
In mid-LV cross-sections, myocyte cross-sectional area
(hematoxylin and eosin; H&E), interstitial collagen content
(Sirius Red), and fibrosis (Masson’s trichrome) were assessed
using ZEN.32 Myocardial expression of plasminogen activator-
inhibitor (PAI)-1 (Catalog No.: ab66705; Abcam), tissue-
inhibitor of metalloproteinases (TIMP)-1 (sc-5528; Santa Cruz
Biotechnology), and transforming growth-factor (TGF)-b (sc-
52891; Santa Cruz Biotechnology) was determined by
Western blot.8
Cardiolipin Content and Mitochondrial Biogenesis
Mitochondrial content was assessed by immunofluorescence
staining with the mitochondrial outer membrane marker
preprotein, translocases of the outer membrane (TOM)-20
(1:50; Santa Cruz Biotechnology, Inc., Dallas, TX).33 Cardi-
olipin content was assessed by enhanced multidimensional
mass spectrometry (MS)-based shotgun lipidomics34 and
immunofluorescence staining (10N-nonyl acridine-orange,
A1372; Invitrogen, Carlsbad, CA),8 and results adjusted by
mitochondrial density (TOM-20 expression). Intensity and
percentage of area stained were quantified semiautomatically
in 10 to 15 random fields (ZEN 2012 blue edition; Carl Zeiss
SMT, Oberkochen, Germany). For MS, lipids were extracted
from the tissue sample with a chloroform/methanol solution
(Bligh Dyer extraction). Individual lipid extracts were recon-
stituted with chloroform:methanol (1:1), flushed with N2, and
then stored at 20°C before analysis by electrospray
ionization MS using a triple-quadruple mass spectrometer
equipped with an automated nanospray apparatus. Enhanced
multidimensional MS-based shotgun lipidomics for cardiolipin
was performed as previously described.34 Cardiolipin con-
tains 2 phosphate heads groups, 3 glycerol moieties, and 4
fatty acid acyl chains. More than 100 molecular fatty acid
species of cardiolipin have been identified including shorter
chain saturated and monounsaturated fatty acids (C16:0,
C18:0, and C18:1) and polyunsaturated fatty acids (C18:2,
C20:4, and C22:6).35 In animal species, cardiolipin contains
almost exclusively 18-carbon fatty acids, and 80% of these
are typically linoleic acid (tetra-linoleoyl cardiolipin [C18:2]).
MS also detects fragments of other cardiolipin molecular
species including fatty acids palmitoleic (C16:1), palmitic
(C16:0), oleic (C18:1), stearic (C18:0), and arachidonic
(C20:4) acid.36
Additionally, myocardial mRNA expression of taffazin (Taz)-
1 was measured by quantitative real-time polymerase chain
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reaction (RT-PCR) using the delta-delta CT method with
validated TaqMan primers from Life Technologies (Carlsbad,
CA) according to the Minimum Information for Publication of
Quantitative Real-Time PCR Experiments (MIQE),19 whereas
protein expression of Taz-1 (Catalog No.: ab105104; Abcam),
cardiolipin synthase (CRLS)-1 (Catalog No.: LS-B12635;
Lifespan Biosciences), and Acyl-CoA:lysocardiolipin acyltrans-
ferase (ALCAT)-1 (Catalog No.: NBP1-59347; Novus Biologi-
cals, LLC, Littleton, CO) was measured by Western blot.
In addition, mitochondria were isolated using the MITO-ISO
kit (Catalog No.: 8268; ScienCell, Carlsbad, CA),33 and protein
expression of the mitochondrial biogenesis markers peroxi-
some proliferator-activated receptor-c-coactivator (PGC)-1a
(1:1000; Abcam), nuclear respiratory factor (NRF)-1 (1:300;
Abcam), GA-binding protein (GABP; 1:1000; Abcam), and
peroxisome proliferator-activated receptor (PPAR)-a (1:1000;
Abcam) measured by Western blot.21
Microvascular Structure and Coronary
Endothelial Function
The proximal left anterior descending artery was cannulated
and perfused under physiological pressure with a radiopaque
contrast agent (MV-122; Flow Tech, Carver, MA). An LV
transmural portion (2 cm3) was scanned, and images ana-
lyzed, as described.32 The spatial density and average
diameter of microvessels in the subepicardium and subendo-
cardium were calculated using Analyze, and vessel tortuosity
(maturity index) calculated. For tissue analysis, media-to-
lumen ratio was calculated in randomly selected intramyocar-
dial vessels in a-SMA-stained sections (DakoCytomation A/S,
Glostrup, Denmark), and myocardial expression of vascular
endothelial growth factor (VEGF) measured by Western blot
(1:200; Santa Cruz Biotechnology).21
To assess coronary vascular function ex vivo, coronary
arteries were dissected immediately after euthanasia (1 ring/
animal per chamber), precontracted with endothelin-1
(107 mol/L), and the response to cumulative concentrations
of the endothelium-dependent bradykinin (1010–105 mol/
L) or endothelium-independent sodium nitroprusside (SNP;
1010–104 mol/L) studied. The method has been previously
described in detail.37–39 Coronary artery sections (2–3 mm
long) were dissected under a dissecting microscope and
placed in 25-mL organ chambers (1 ring from each animal per
chamber) filled with Kreb’s solution at 37°C (pH=7.4, 95% O2,
and 5% CO2). Each ring was suspended by 2 stainless clips, 1
attached to a stationary post and the other to a strain gauge
to measure isometric force (Statham Gould UC 2; Viggo
Spectamed, Critical Care Division, Oxnard, CA). Rings were
progressively stretched (potassium chloride 20 mmol/L) to
achieve the optimal point for their length-tension relationship.
After an equilibration period of 30 minutes, the vessels were
precontracted with endothelin-1 (107 mol/L), and then
the response to cumulative concentrations of bradykinin
(1010–105 mol/L) was recorded to evaluate endothelium
dependent relaxation. The same experiments were repeated
using increasing concentrations of SNP (1010 to 104 mol/
L) as an endothelium-independent vasodilator. Cardiolipin
content (10N-nonyl-acridine-orange), mitochondrial UCP-2
(Abcam, catalog# ab97931), apoptosis (TUNEL), superoxide
anion production (DHE), and endothelial NO synthase (eNOS;
Catalog No.: ab5589; Abcam) expression were assessed in
coronary artery sections.19
Cardiomyoblast Studies
To affirm the ability of MTP to directly blunt mitochondrial
injury, H9c2 rat cardiomyoblast (CM; ATCC CRL-1446) were
grown in staining chamber slides untreated or treated for
4 hours with the MTP, Bendavia, 1 lmol/L and/or tert-butyl
hydroperoxide (tBHP) 25 mmol/L13 (6 wells/group). Cells
were cultured and maintained at 37°C in MEM 10% culture
media supplemented with 10% FBS, as previously described.40
Then, CM were divided into 4 groups (6 wells per group),
which were grown in staining chamber slides untreated or
treated with either the MTP, Bendavia, 1 lmol/L, tert-butyl
hydroperoxide (tBHP) 25 mmol/L that causes lipid peroxida-
tion and mitochondrial dysfunction13,41 or tBHP+MTP for
4 hours. CM were subsequently stained for cardiolipin (10N-
nonyl acridine orange)19,21 and Mito-SOX for detection of
mitochondrial ROS production. In addition, an XF24 Analyzer
(Seahorse Biosciences, North Billerica, MA) was used to
measure bioenergetic function in intact CM, CM+MTP,
CM+tBHP, and CM+tBHP+MTP in real time. Cells were
seeded into Seahorse Bioscience XF24 cell culture plates at
a population density of approximately 100 000/well in
250 lL of media and allowed to adhere and grow for
24 hours in a 37°C humidified incubator with 5% CO2. Media
were changed 1 hour before the start of the extracellular flux
assay to unbuffered (pH 7.4) DMEM containing 2 mmol/L of
GlutaMax, 1 mmol/L of sodium pyruvate, and supplemented
with 25 mmol/L of glucose and incubated at 37°C without
CO2. The XF24 protocol consists of 4 measurements (2 min-
utes mix/2 minutes measure) of basal oxygen consumption
rate (OCR; an indicator of mitochondrial respiration) followed
by 3 measures after addition of 9 lmol/L of Oligomycin (ATP
uncoupler), 0.3 lmol/L of carbonyl cyanide p-trifluoro-
methoxy-phenylhydrazone (FCCP; electron transport chain
accelerator), and a combination of 11 lmol/L of Antimycin-A
(Complex-III inhibitor) and 11 lmol/L of Rotenone (Complex-I
inhibitor). Basal respiration, ATP production (Basal respiration-
Oligomycin response), Proton leak (Oligomycin response-
Antimycin-A and Rotenone response), and Maximal respiration
(Basal respiration-non-mitochondrial respiration) were
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calculated, following standard procedures.42 On completion of
the XF assay, cells were lysed with CellLytic MT lysis reagent
(200 lL/well) and protein concentration determined using
the Bradford reagent. OCR data are expressed as pmol/
minutes per mg of protein.
Statistical Analysis
Statistical analysis was performed using JMP software (ver-
sion 10.0). Results are expressed as meanSD or median and
interquartile range (IQR) and compared with ANOVA/Kruskal
Wallis followed by Student t test/Wilcoxon. Statistical signif-
icance was accepted if P≤0.05.
Results
At 16 weeks, all HC-RVH animals developed significant and
similar levels of hypertension (Table). Serum creatinine was
higher in HC-RVH+Vehicle compared to normal, but normal-
ized in HC-RVH+MTP. PRA levels were similar among the
groups. Cholesterol levels were elevated in HC-RVH, whereas
triglycerides were unaltered (Table).
Cardiac Oxygenation and Function
Heart rate, stroke volume, and ejection fraction were similar
among the groups (Table; P>0.05, ANOVA). LVMM was higher
in HC-RVH+Vehicle compared to normal, but restored in HC-
RVH+MTP. E/A ratio, which decreased in HC-RVH+Vehicle,
was also normalized in HC-RVH+MTP (P=0.03 vs HC-
RVH+Vehicle; P=0.21 vs normal), as was EDV (P=0.02 vs
HC-RVH+Vehicle, P=0.86 vs normal).
Baselinemyocardial perfusion and its response to adenosine
were decreased in HC-RVH+Vehicle, but normalized in HC-
RVH+MTP (Table). Furthermore, baseline R2* was elevated in
HC-RVH+Vehicle compared to normal, suggesting decreased
oxygenation, but normalized in HC-RVH+MTP (Figure 1B).
Similarly, R2* response to adenosine was blunted in RVH+Vehi-
cle, but restored to normal levels in HC-RVH+MTP.
Myocardial Injury and Remodeling
The number of TUNEL-positive cells was elevated in both HC-
RVH groups, yet lower in HC-RVH+MTP compared to HC-
RVH+Vehicle (Figure 2A). TUNEL-positive staining colocalized
with connexin-43, suggesting apoptotic cardiomyocytes.
Table. Systemic Characteristics, Renal Hemodynamics, and Function of Study Groups (n=7 Each) at 16 Weeks
Parameter Normal+Vehicle Normal+MTP HC-RVH+Vehicle HC-RVH+MTP
Degree of stenosis (%) 0 (0–0) 0 (0–0) 95.0 (77.5–99.5)*,† 85.0 (62.5–87.5)*,†
Body weight, kg 49.31.5 49.81.7 47.81.3 48.32.8
Mean blood pressure, mm Hg 78.7 (75.9–82.8) 81.3 (77.0–84.0) 123.0 (117.7–125.0)*,† 123.7 (119.2–127.8)*,†
Serum creatinine, mg/dL 1.40.2 1.50.1 1.90.2* 1.50.3
Plasma renin activity, ng/mL/h 0.130.07 0.130.15 0.170.10 0.160.08
Cholesterol, mg/dL: Total 88.0 (86.0–122.0) 88.5 (79.5–91.5) 519.0 (426.0–545.0)*,† 491.0 (443.0–653.0)*,†
HDL 37.0 (28.0–66.0) 46.0 (41.5–55.0) 169.0 (147.0–180.0)*,† 166.0 (154.0–180.0)*,†
LDL 54.0 (47.6–58.0) 37.3 (33.4–40.8) 324.6 (298.8–375.0)*,† 287.4 (213.8–385.0)*,†
Triglycerides, mg/dL 9.01.7 9.34.3 6.52.9 5.82.8
Heart rate, bpm 71.79.5 77.08.1 79.810.1 75.02.2
Stroke volume, mL 42.6.35.5 44.35.9 47.210.8 45.15.8
Ejection fraction, % 58.510.0 58.14.4 60.07.0 60.86.1
LVMM, g/kg 1.7 (1.6–1.8) 1.6 (1.5–1.7) 2.5 (1.7–3.2)*,†,‡ 1.8 (1.7–1.9)†
E/A ratio 1.20.3 1.00.1 0.70.3*,‡ 1.00.2
EDV, mL 85.012.5 79.710.2 68.28.4*,‡ 83.711.4
Myocardial perfusion, mL/min per g
Baseline 0.8 (0.7–1.3) 0.8 (0.7–0.9) 0.7 (0.6–0.8)*,‡ 0.7 (0.7–0.8)
Response to adenosine 0.9 (0.8–1.5)§ 0.8 (0.8–1.0)§ 0.7 (0.6–0.8)*,†,‡ 0.8 (0.7–1.0)§
E/A indicates early and late left ventricular filling ratio; EDV, end-diastolic volume; HC-RVH, hypercholesterolemic renovascular hypertension; HDL, high-density lipoprotein; LDL, low-
density lipoprotein; LVMM, left ventricular muscle mass; MTP, mitochondrial-targeted peptides.
*P<0.05 vs Normal+Vehicle.
†
P<0.05 vs Normal+MTP.
‡
P<0.05 vs HC-RVH+MTP.
§
P<0.05 vs baseline.
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Figure 2. Mitochondrial-targeted peptides (MTP) attenuate myocardial apoptosis and oxidative stress. A,
The number of cells positive for terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL;
green) was elevated in renovascular hypertension (RVH), but decreased in RVH+MTP. Red: connexin-43. B,
Myocardial protein expression of B-cell lymphoma (Bcl)-xl was upregulated in RVH+MTP pigs. C, In situ
myocardial production of superoxide anion (dihydroethidium; DHE) decreased in RVH pigs treated with MTP.
D, Myocardial expression of the nicotinamide adenine dinucleotide phosphate (NADPH)-oxidase subunits,
p47 and gp91, were elevated in RVH, but gp91 expression normalized in RVH+MTP. E, Total reactive oxygen
species (ROS) burden was higher in RVH+Vehicle, yet normalized in MTP-treated RVH. *P<0.05 vs
Normal+Vehicle; #P<0.05 vs Normal+MTP; †P<0.05 vs hypercholesterolemic (HC)-RVH+MTP. GAPDH
indicates glyceraldehyde-3-phosphate dehydrogenase; TUNEL, terminal deoxynucleotidyl transferase dUTP
nick end labeling.
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Myocardial expression of Bcl-xl was upregulated in HC-
RVH+MTP compared to HC-RVH+Vehicle and to normal pigs
(Figure 2B).
Superoxide anion production was higher in the HC-RVH
myocardium compared to normal, yet restored in HC-
RVH+MTP (Figure 2C). Myocardial expression of p47 and
gp91 was elevated in HC-RVH+Vehicle compared to normal,
but only gp91 expression was downregulated in MTP-treated
HC-RVH (Figure 2D), as was total ROS burden (Figure 2E).
SERCA-2a protein levels and activity fell in HC-RVH and its
affinity for calcium was lower than normal (higher SERCA-2a
activity K0.5), but both were restored in HC-RVH+MTP
(Figure 3A through C). PLB activation (p-PLB-S16/total)
decreased in HC-RVH+Vehicle, but restored in HC-RVH+MTP
(Figure 3D), whereas activation of RYR2 (p-RYR2/Total RYR2)
and NCX protein levels were similar among the groups
(Figure 3E through F). Although total VDAC and RYR fluores-
cence did not differ among the groups, their overlap
coefficient (M1) decreased in HC-RVH groups, but improved
in HC-RVH+MTP (Figure 4).
Myocyte cross-sectional area in HC-RVH was higher than
normal, and myocardial collagen deposition (Sirius Red) and
fibrosis were increased, but all improved in HC-RVH+MTP
(Figure 5A). Myocardial PAI-1 expression was similarly upreg-
ulated in both HC-RVH groups, whereas TIMP-1 and TGF-b
expression improved in HC-RVH+MTP (Figure 5B).
Cardiolipin Content and Mitochondrial Biogenesis
Myocardial expression of the outer mitochondrial membrane
protein, TOM-20, was similar among groups, suggesting
preserved mitochondrial content. Contrarily, cardiolipin con-
tent was decreased in HC-RVH+Vehicle, but normalized in HC-
RVH+MTP (Figure 6A and 6B). The most prominent molecular
species, tetra-linoleoyl cardiolipin (C18:2) followed by C20:4,
both decreased in HC-RVH+Vehicle, but normalized in HC-
RVH+MTP (Figure 6C), as was mRNA expression of taz-1
(Figure 6D). Myocardial protein expression of Taz-1 was
similarly blunted in HC-RVH+Vehicle and HC-RVH+MTP (Fig-
ure 6E), whereas expression of ALCAT-1 and CRLS-1 did not
differ among the groups. Furthermore, expression of PGC-1a,
decreased in HC-RVH+Vehicle, was normalized in HC-
RVH+MTP (Figure 7). Although NFR-1 expression was
unchanged, GABP and PPAR-a expression was downregulated
in HC-RVH+Vehicle, but not in HC-RVH+MTP.
Vascular Structure and Function
Spatial density of subepicardial microvessels was similar
among the groups, whereas density of small (0.02–0.02 mm)
subendocardial microvessels decreased in HC-RVH, but
improved in HC-RVH+MTP (Figure 8A). Similarly, transmural
vessel tortuosity was higher in both RVH groups compared to
normal, but lower in HC-RVH+MTP pigs (Figure 8B). Myocar-
dial expression of VEGF was upregulated in HC-RVH+MTP
(Figure 8C), whereas vessel wall-to-lumen ratio, which was
higher in both HC-RVH groups compared to normal, improved
in MTP-treated pigs (Figure 8D).
The vasorelaxation response to bradykinin in excised HC-
RVH coronary vessels was attenuated compared with normal,
but improved (although not normalized) in HC-RVH+MTP,
whereas response to SNP was unchanged (Figure 9A).
Cardiolipin staining in coronary artery sections was blunted
in HC-RVH+Vehicle, but restored in HC-RVH+MTP (Figure 9B),
as were the number of TUNEL-positive cells and the
immunoreactivity of eNOS and UCP-2. Finally, superoxide
anion production was elevated in HC-RVH+Vehicle, but
decreased in HC-RVH+MTP animals (Figure 9B).
CM Studies
Incubation with tBHP decreased CM cardiolipin expression,
which normalized upon coincubation with MTP (Figure 10A).
Mitochondrial ROS levels were upregulated in both tBHP-
treated groups, but improved in CM+tBHP+MTP (Figure 10B).
Furthermore, basal respiration, ATP production, and maximal
respiration were blunted in CM+tBHP, but improved in
CM+tBHP+MTP (Figure 10C), whereas proton leak remained
unaltered.
Discussion
The current study demonstrates that experimental HC-RVH
induces cardiolipin loss, myocardial injury, and impaired LV
function, and that hypertension notwithstanding, stabilization
of mitochondrial cardiolipin can attenuate these changes.
These findings support the concept that myocardial cardi-
olipin loss partly contributes to hypertension-induced LV
remodeling and impaired relaxation, and that mitochondrial-
targeted peptides can effectively ameliorate them in swine
HC-RVH.
We have previously shown that adjunct short-term MTP
therapy during renal revascularization in swine HC-RVH
improved diastolic function and myocardial tissue integrity,
supporting a role for MTP for cardiac protection during
regression of HC-RVH.8 The current study extends our
previous observations demonstrating that chronic MTP deliv-
ery restored cardiolipin content and cardiac integrity despite
sustained RVH.
RVH can initially induce cardiac remodeling associated with
isolated LV diastolic dysfunction, increasing cardiovascular
morbidity and mortality.43,44 Patients with RVH exhibit a high
prevalence of LV hypertrophy and progressive LV dilatation.45
Indeed, LV remodeling and relaxation are worse in RVH
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Figure 3. Mitoprotection preserved calcium cycling activity. Thapsigargin-sensitive sarcoplasmic reticu-
lum (SR) Ca2+-ATPase (SERCA)-2a protein levels (A) and activity (B) were reduced in renovascular
hypertensive (RVH) pigs, whereas SERCA-2a activity K0.5 was elevated (C), but all were improved in
RVH+Mitochondrial-targeted peptides (MTP) pigs. Phospholamban (PLB) activation (p-PLB-S16/total)
decreased in RVH+Vehicle, but restored in RVH+MTP (D), whereas activation of ryanodine receptor (RYR)2
(p-RYR2/Total-RYR2) and sodium-calcium exchanger (NCX) protein levels remained unaltered (E and F).
*P<0.05 vs Normal+Vehicle; †P<0.05 vs hypercholesterolemic (HC)-RVH+MTP.
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compared with essential hypertensive patients,3 warranting
development of preventive strategies in these patients.
Mitochondria comprise one third of cardiomyocyte volume
and regulate ATP and calcium homeostasis required for
sustaining cardiomyocyte viability and contractility.46 Further-
more, endothelial cell mitochondria modulate intracellular
ROS, NO, and calcium, which regulate endothelial cell
function.47 Importantly, mitochondria also control cell prolif-
eration and death (apoptosis and necrosis), cellular oxidative
stress, and intracellular calcium homeostasis. However, the
involvement of mitochondrial injury in RVH-induced LV
dysfunction remains incompletely understood.
In the present study, we found that despite preserved
mitochondrial content (TOM-20 expression), HC-RVH induced
mitochondrial injury, characterized by decreased cardiolipin
content, and mRNA and protein expression of its main
remodeling enzyme, taz-1. Contrarily, myocardial expression
of ALCAT-1 and CRLS-1 remained unaltered, suggesting that
HC-RVH affects primary (rather than salvages) cardiolipin
remodeling (ALCAT-1)48 or de novo synthesis (CRLS-1).49 The
most prominent molecular species that decreased in HC-
RVH+Vehicle was the tetra-linoleoyl, cardiolipin (C18:2). This
contrasts with the increase in C20:4 and C22:6 reported in
murine models of heart failure,50,51 possibly attributed to
differences in animal model, disease duration, or interspecies
variability. Although MTP improved Taz-1 mRNA expression,
this did not suffice to restore its protein expression, arguing
against a major role of MTP in preserving primary cardiolipin
remodeling.
Furthermore, loss of cardiolipin impaired mitochondrial
biogenesis, reflected in decreased expression of PGC-1a, a
major regulator of mitochondrial biogenesis that activates
several transcription factors, including NRF-1, GABP, and PPAR-
a.52,53 In our study, although HC-RVH downregulated PGC-1a,
Figure 4. Mitochondrial-targeted peptides (MTP) improved mitochondria-sarcoplasmic reticulum func-
tional coupling. Double immunofluorescence of the mitochondrial membrane through a voltage-dependent
anion channel (VDAC) and the sarcoplasmic reticulum marker, ryanodine receptor (RYR, top), and
quantification of total VDAC and RYR fluorescence, and Mander’s coefficient colocalization. $P<0.05 vs
VDAC; *P<0.05 vs Normal+Vehicle; #P<0.05 vs Normal+MTP; †P<0.05 vs hypercholesterolemic renovas-
cular hypertension (HC-RVH)+MTP. a.u.f. indicates relative arbitrary units.
DOI: 10.1161/JAHA.115.003118 Journal of the American Heart Association 10
Mitochondria in Cardiac Dysfunction Eirin et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
GABP, and PPAR-a myocardial expression, NRF-1 levels
remained unchanged, suggesting early changes in expression
of mitochondrial biogenesis proteins. Given that cardiolipin
content remained unchanged, defects in mitochondrial biogen-
esis might precede changes in their content. Furthermore, HC-
RVH-induced primary cardiolipin remodeling may trigger mPTP
formation and cytochrome-c release (Figure 11), promoting
cardiomyocyte apoptosis (by TUNEL). Interestingly, HC-RVH
increased myocardial expression of the antiapoptotic, Bcl-xl,
possibly as a compensatorymechanism,54 which did not suffice
to alleviate apoptosis. Moreover, mPTP opening favors release
of mitochondrial-ROS to the cytosol, triggering cardiomyocyte
oxidative stress (increased total ROS burden, superoxide anion
production, and gp91 expression).
Figure 5. Mitoprotection ameliorates myocardial remodeling and fibrosis in renovascular hypertension
(RVH). A, Myocyte cross-sectional area (hematoxylin and eosin; H&E), collagen deposition (Sirius Red), and
fibrosis (Trichrome) were attenuated in mitochondrial-targeted peptides (MTP)-treated pigs. B, Myocardial
expression of plasminogen activator inhibitor (PAI)-1 was higher in all RVH pigs, but expression of tissue
inhibitor of metalloproteinase (TIMP)-1 and transforming growth factor (TGF)-b was decreased in RVH+MTP.
*P<0.05 vs Normal+Vehicle; #P<0.05 vs Normal+MTP; †P<0.05 vs hypercholesterolemic (HC)-RVH+MTP.
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Furthermore, MTP ameliorated HC-RVH-induced cardiomy-
ocyte apoptosis, possibly by preventing mPTP formation and
consequent cytochrome-c release. Inhibition of mPTP opening
and increased electron transport chain efficiency might have
also prevented mitochondrial ROS release, thereby decreasing
myocardial oxidative stress in HC-RVH+MTP. Nevertheless,
myocardial hypoxia and microvascular rarefaction might
have also contributed to myocardial oxidative damage in
HC-RVH+Vehicle pigs, and, in turn, damaged the mitochon-
dria, creating a vicious cycle of myocardial injury and oxidative
stress.
Taken together, our observations suggest that HC-RVH-
induced cardiomyopathy involves decreased cardiolipin con-
tent and impaired mitochondrial biogenesis, leading to
increased myocardial oxidative stress and apoptosis, which
can be attenuated by cardiolipin restoration. Furthermore,
Figure 6. Mitochondrial-targeted peptides (MTP) restored cardiolipin content. A, Representative
immunofluorescent staining of the mitochondrial outer membrane marker pre-protein, translocases of
the outer membrane (TOM)-20 (green), and cardiolipin (red) showing decreased myocardial cardiolipin
expression in renovascular hypertension (RVH) despite preserved mitochondrial content, which was
normalized in RVH+MTP. B and C, Total cardiolipin content and its prominent molecular species (mass
spectrometry) were restored in MTP-treated RVH animals. D, Tafazzin (Taz)-1 mRNA expression was
downregulated in RVH, yet normalized in RVH+MTP. E, Myocardial expression of cardiolipin synthase
(CRLS)-1, Taz-1, and Acyl-CoA:lysocardiolipin acyltransferase (ALCAT)-1 in study groups. *P<0.05 vs
Normal+Vehicle; #P<0.05 vs Normal+MTP; †P<0.05 vs hypercholesterolemic (HC)-RVH+MTP.
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studies in CM exposed to lipid peroxidation and mitochondrial
injury confirmed that loss of cardiolipin increased mitochon-
drial ROS production and impaired basal respiration, ATP
production, and maximal respiration, and that MTP directly
attenuates mitochondria-derived oxidative stress and restores
bioenergetics. However, unlike other mitochondria-targeted
compounds, such as mitoQ, mitoTempol, and mitoE, that
inhibit proton leak,55 MTP had no effect on proton leak. These
observations suggest that mechanisms other than inhibiting
mPTP opening, such as improved efficiency of energy
production and utilization, might have mediated its cardio-
protective effect.
Interestingly, mitoprotection restored intracellular calcium
cycling in HC-RVH. Mitochondria are closely associated to the
calcium release sites of the sarcoplasmic reticulum, facilitating
calcium entry through the mitochondrial channel VDAC,56 and
uncoupled sarcoplasmic reticulum-mitochondria communica-
tion amplifies myocardial oxidative stress.31,57 The current
study applied the Manders overlap coefficient to quantify the
degree of overlap and codistributions of mitochondria (VDAC)
and sarcoplasmic reticulum (RYR) probes in each pixel of
fluorescence staining images. This method examines mathe-
matically the degree to which the variability in red and green co-
occurrence (i.e., for each pixel, both are above background) can
be explained with a simple, linear relationship between the
two.58 We found that HC-RVH interferes with mitochondrial and
sarcoplasmic reticulum juxtaposition (VDAC and RYR), which
MTP improved, preservingmyocardial calcium cycling enzymes.
Indeed, the fall in myocardial SERCA-2a and PLB activities and
SERCA-2a expression59 in our HC-RVH model support the
functional MDCT findings of impaired LV relaxation. Impor-
tantly, mitochondria can sequester calcium, impacting its
cytosolic concentration and modulating the activity of mem-
brane channels and transporters,60 particularly SERCA-2a.61
Despite sustained hypertension, mitoprotection restored
SERCA-2a levels, activity, and affinity for calcium, and improved
p-PLB-S16 expression. In contrast, RYR2 remained unaltered,
suggesting preserved systolic function, underscoring the early
stage of RVH.
Notably, our study implicates mitochondrial injury in the
pathogenesis of RVH-induced myocardial microvascular rar-
efaction. Mitochondria orchestrate essential aspects of
control of vascular tone and angiogenesis by regulating
ROS, cell proliferation, apoptosis, and calcium signaling. For
example, mitochondrial injury regulates eNOS activation in
endothelial cells,62,63 apoptosis, and endothelial dysfunc-
tion,64 underscoring our findings. Therefore, endothelial cell
apoptosis and oxidative stress attributed to cardiolipin loss
might have accounted for HC-RVH-induced microvascular loss
and endothelial dysfunction. Furthermore, myocardial apop-
tosis and oxidative stress modulate microvascular architec-
ture65 and might have thereby affected microvascular
remodeling and function. Strikingly, spatial density and
morphology of small subendocardial microvessels improved
in MTP-treated HC-RVH pigs, despite unaffected blood
pressure possibly owing to PGC-1a-stimulated secretion of
VEGF and other angiogenic factors.66
Possibly consequent to impaired angiogenesis and
microvascular architecture, myocardial oxygenation, perfu-
sion, and its response to intravenous adenosine were slightly
attenuated in HC-RVH+Vehicle. Given that both perfusion
and oxygenation normalized in HC-RVH+MTP, mitochondrial
injury likely contributes to functionally consequent vascular
dysfunction. Indeed, chronic mitoprotection improved coro-
nary endothelial function ex vivo, possibly by restoring
cardiolipin, decreasing superoxide anion production, improv-
ing eNOS immunoreactivity, or other mechanisms regulated
by mitochondria of endothelial cells.67 Furthermore, this
Figure 7. Mitochondrial-targeted peptides (MTP) induce mitochondrial biogenesis. Myocardial protein
expression of the mitochondrial biogenesis markers, peroxisome proliferator-activated receptor-c-
coactivator (PGC)-1a, nuclear respiratory factor (NFR), GA-binding protein (GABP), and peroxisome
proliferator–activated receptor (PPAR)-a. *P<0.05 vs Normal+Vehicle; #P<0.05 vs Normal+MTP; †P<0.05 vs
hypercholesterolemic (HC)-renovascular hypertension (RVH)+MTP.
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approach improved expression of the mitochondrial trans-
porter UCP-2, which regulates mitochondrial ROS formation
in ischemia.68
Mitochondrial ROS has been shown to contribute directly
to the development of cardiac hypertrophy and fibrosis.69
We found that mitochondrial injury and increased ROS,
which exert direct effects on cardiac fibroblasts,70 were
associated with upregulated expression of the profibrotic
mediators, TGF-b, PAI-1, and TIMP-1. Additionally, myocar-
dial apoptosis, oxidative stress, and hypoxia might have
Figure 8. Mitoprotection preserved microvascular structure. A, Representative 3-dimensional micro-
computed-tomography images of the left ventricle and quantification of spatial density of subendocardial
microvessels. B, Vessel tortuosity was higher in renovascular hypertension (RVH) compared to normal, but
slightly decreased in RVH+ Mitochondrial-targeted peptides (MTP). C, Myocardial protein expression of
vascular endothelial growth factor (VEGF) was upregulated in RVH+MTP. D, Myocardial vessel wall-to-lumen
ratio in a-smooth muscle actin stained slides. *P<0.05 vs Normal+Vehicle; #P<0.05 vs Normal+MTP;
†P<0.05 vs hypercholesterolemic (HC)-RVH+MTP.
DOI: 10.1161/JAHA.115.003118 Journal of the American Heart Association 14
Mitochondria in Cardiac Dysfunction Eirin et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
also contributed to the development of fibrosis in our
model. Although blood pressure remained elevated, myocar-
dial hypertrophy, fibrosis, and, in turn, LV relaxation and
diastolic filling, all improved in HC-RVH+MTP, underscoring
a link between myocardial fibrosis and mitochondrial
damage.71 Importantly, expression of TIMP-1 and TGF-b,
major contributors of myocardial fibrosis,72,73 decreased in
HC-RVH+MTP.
Our study is limited by the use of relatively young animals
and by the short duration of HC-RVH compared to the human
Figure 9. Mitochondrial-targeted peptides (MTP) improve coronary endothelial function. A, Endothelial-
dependent (left) and -independent (right) relaxation of coronary segments from normal and renovascular
hypertensive (RVH) pigs 4 weeks after chronic subcutaneous injections of MTP or Vehicle. B,
Representative images and quantification of cardiolipin expression (10N-nonyl-acridine-orange), apoptosis
(terminal deoxynucleotidyl transferase dUTP nick-end labeling; TUNEL), uncoupling protein (UCP)-2
expression, in situ production of superoxide anion (dihydroethidium; DHE), and endothelial nitric oxide
synthase (eNOS) immunoreactivity in coronary artery sections. *P<0.05 vs Normal+Vehicle; #P<0.05 vs
Normal+MTP; †P<0.05 vs hypercholesterolemic (HC)-RVH+MTP.
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disease. Nevertheless, myocardial structure and function in
the swine model mimic those observed in human RVH,
providing a unique opportunity to evaluate the role of the
mitochondria in a preclinical setting. Additional traditional
parameters of LV compliance and diastolic function remain to
be assessed in future studies. Some of the benefits observed
Figure 10. Mitochondrial-targeted peptides (MTP) improved mitochondrial bioenergetics in cultured
cardiomyocytes. Cardiolipin expression decreased (A) and mitochondrial reactive oxygen species
production (B) increased in normal cardiomyoblasts (CM) treated with tert-butyl hydroperoxide (tBHP),
but improved in cells coincubated with MTP. C, Representative tracing of oxygen consumption in CM,
CM+MTP, CM+tBHP, and CM+tBHP+MTP under basal conditions, and after the addition of Oligomycin (ATP
uncoupler), 0.3 lmol/L of carbonyl cyanide p-trifluoromethoxy-phenylhydrazone (FCCP, electron transport
chain accelerator), and a combination of 11 lmol/L of Antimycin-A (Complex-III inhibitor) and 11 lmol/L
of Rotenone (Complex-I inhibitor), and quantification of basal respiration, ATP production, maximal
respiration, and proton leak in study groups. *P<0.05 vs CM; #P<0.05 vs CM+MTP; †P<0.05 vs
CM+tBHP+MTP.
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in the myocardium might have also been secondary to renal
improvement.19 However, the unchanged plasma renin activ-
ity argues against systemic activation of the renin/an-
giotensin system. Additionally, some measurements were
not available in Normal+MTP animals. Yet, similar to the
normal kidney,5,19 treatment of normal animals with MTP did
not affect myocardial structure and function, suggesting that
MTP does not measurably affect normal organs. Finally,
mitochondrial membrane potential and respiration rate may
interfere with cardiolipin staining.74 Therefore, we also
assessed cardiolipin content by MS.
In summary, our study demonstrates that HC-RVH leads to
cardiolipin loss and impaired mitochondrial biogenesis, pos-
sibly secondary to cellular oxidative stress, which, in turn,
mediates cellular and vascular injury. Despite unchanged
blood pressure, mitochondrial protection restores cardiolipin
levels, improves cardiac relaxation and structure, normalizes
calcium cycling activity, and improves coronary vascular
remodeling and endothelial function. These findings under-
score the vulnerability of the mitochondria and the contribu-
tion of mitochondrial injury to RVH-induced cardiac
remodeling and dysfunction. Yet, future studies are needed
to establish a cause-effect relationship and test the cardio-
protective properties of MTP as a novel therapeutic strategy
to decrease cardiac damage and improve LV relaxation in
human RVH.
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Figure 11. Proposed mechanisms implicated in renovascular hypertension–induced myocardial injury.
Cardiolipin remodeling and loss impairs mitochondrial biogenesis and bioenergetics. Furthermore, loss of
cardiolipin triggers mitochondria permeability transition pore opening and release of cytochrome-c and
reactive oxygen species to the cytosol, increasing myocardial cell apoptosis and oxidative stress. This
instigates microvascular remodeling and endothelial dysfunction, as well as myocardial hypoxia, collagen
deposition, and fibrosis. Mitochondrial dysfunction also alters mitochondria-sarcoplasmic-reticulum
interaction, impairing calcium cycling. Finally, myocardial remodeling and altered sarcoplasmic-reticulum
calcium cycling leads to impaired left ventricular (LV) relaxation.
DOI: 10.1161/JAHA.115.003118 Journal of the American Heart Association 17
Mitochondria in Cardiac Dysfunction Eirin et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
Disclosures
Dr. Amir Lerman is a consultant to Stealth Biopharmaceu-
ticals, Inc.
References
1. Chrysochou C, Kalra PA. Atherosclerotic renovascular disease and the heart. J
Ren Care. 2010;36(suppl 1):146–153.
2. Green D, Kalra PA. The heart in atherosclerotic renovascular disease. Front
Biosci (Elite Ed). 2012;4:856–864.
3. Khangura KK, Eirin A, Kane GC, Misra S, Textor SC, Lerman A, Lerman LO.
Cardiac function in renovascular hypertensive patients with and without renal
dysfunction. Am J Hypertens. 2014;27:445–453.
4. Eirin A, Lerman A, Lerman LO. Mitochondrial injury and dysfunction in
hypertension-induced cardiac damage. Eur Heart J. 2014;35:3258–3266.
5. Eirin A, Lerman A, Lerman LO. Mitochondria: a pathogenic paradigm in
hypertensive renal disease. Hypertension. 2015;65:264–270.
6. Dai DF, Chen T, Wanagat J, Laflamme M, Marcinek DJ, Emond MJ, Ngo CP,
Prolla TA, Rabinovitch PS. Age-dependent cardiomyopathy in mitochondrial
mutator mice is attenuated by overexpression of catalase targeted to
mitochondria. Aging Cell. 2010;9:536–544.
7. Arnaudeau S, Kelley WL, Walsh JV Jr, Demaurex N. Mitochondria recycle Ca(2+)
to the endoplasmic reticulum and prevent the depletion of neighboring
endoplasmic reticulum regions. J Biol Chem. 2001;276:29430–29439.
8. Eirin A, Williams BJ, Ebrahimi B, Zhang X, Crane JA, Lerman A, Textor SC,
Lerman LO. Mitochondrial targeted peptides attenuate residual myocardial
damage after reversal of experimental renovascular hypertension. J Hypertens.
2014;32:154–165.
9. Topal G, Brunet A, Walch L, Boucher JL, David-Dufilho M. Mitochondrial
arginase ii modulates nitric-oxide synthesis through nonfreely exchangeable l-
arginine pools in human endothelial cells. J Pharmacol Exp Ther.
2006;318:1368–1374.
10. Tian XY, Wong WT, Xu A, Lu Y, Zhang Y, Wang L, Cheang WS, Wang Y, Yao X,
Huang Y. Uncoupling protein-2 protects endothelial function in diet-induced
obese mice. Circ Res. 2012;110:1211–1216.
11. Cho YE, Basu A, Dai A, Heldak M, Makino A. Coronary endothelial dysfunction
and mitochondrial reactive oxygen species in type 2 diabetic mice. Am J
Physiol Cell Physiol. 2013;305:C1033–C1040.
12. Schleicher M, Shepherd BR, Suarez Y, Fernandez-Hernando C, Yu J, Pan Y,
Acevedo LM, Shadel GS, Sessa WC. Prohibitin-1 maintains the angiogenic
capacity of endothelial cells by regulating mitochondrial function and
senescence. J Cell Biol. 2008;180:101–112.
13. Birk AV, Liu S, Soong Y, Mills W, Singh P, Warren JD, Seshan SV, Pardee JD,
Szeto HH. The mitochondrial-targeted compound SS-31 re-energizes ischemic
mitochondria by interacting with cardiolipin. J Am Soc Nephrol.
2013;24:1250–1261.
14. Osman C, Voelker DR, Langer T. Making heads or tails of phospholipids in
mitochondria. J Cell Biol. 2011;192:7–16.
15. Szeto HH. First-in-class cardiolipin-protective compound as a therapeutic agent
to restore mitochondrial bioenergetics. Br J Pharmacol. 2014;171:2029–2050.
16. Rytomaa M, Kinnunen PK. Evidence for two distinct acidic phospholipid-
binding sites in cytochrome c. J Biol Chem. 1994;269:1770–1774.
17. Paradies G, Petrosillo G, Paradies V, Ruggiero FM. Mitochondrial dysfunction in
brain aging: role of oxidative stress and cardiolipin. Neurochem Int.
2011;58:447–457.
18. Kloner RA, Hale SL, Dai W, Gorman RC, Shuto T, Koomalsingh KJ, Gorman JH
III, Sloan RC, Frasier CR, Watson CA, Bostian PA, Kypson AP, Brown DA.
Reduction of ischemia/reperfusion injury with bendavia, a mitochondria-
targeting cytoprotective peptide. J Am Heart Assoc. 2012;1:e001644
doi:10.1161/JAHA.112.001644.
19. Eirin A, Ebrahimi B, Zhang X, Zhu XY, Woollard JR, He Q, Textor SC, Lerman A,
Lerman LO. Mitochondrial protection restores renal function in swine
atherosclerotic renovascular disease. Cardiovasc Res. 2014;103:461–472.
20. Chade AR, Zhu X, Mushin OP, Napoli C, Lerman A, Lerman LO. Simvastatin
promotes angiogenesis and prevents microvascular remodeling in chronic
renal ischemia. FASEB J. 2006;20:1706–1708.
21. Eirin A, Li Z, Zhang X, Krier JD, Woollard JR, Zhu XY, Tang H, Herrmann SM,
Lerman A, Textor SC, Lerman LO. A mitochondrial permeability transition
pore inhibitor improves renal outcomes after revascularization in
experimental atherosclerotic renal artery stenosis. Hypertension. 2012;
60:1242–1249.
22. Ebrahimi B, Gloviczki M, Woollard JR, Crane JA, Textor SC, Lerman LO.
Compartmental analysis of renal bold MRI data: introduction and validation.
Invest Radiol. 2012;47:175–182.
23. Rodriguez-Porcel M, Lerman A, Herrmann J, Schwartz RS, Sawamura T,
Condorelli M, Napoli C, Lerman LO. Hypertension exacerbates the effect of
hypercholesterolemia on the myocardial microvasculature. Cardiovasc Res.
2003;58:213–221.
24. Urbieta Caceres VH, Lin J, Zhu XY, Favreau FD, Gibson ME, Crane JA, Lerman A,
Lerman LO. Early experimental hypertension preserves the myocardial
microvasculature but aggravates cardiac injury distal to chronic coronary
artery obstruction. Am J Physiol Heart Circ Physiol. 2011;300:H693–H701.
25. Gupta RC, Shimoyama H, Tanimura M, Nair R, Lesch M, Sabbah HN. Sr Ca(2+)-
atpase activity and expression in ventricular myocardium of dogs with heart
failure. Am J Physiol. 1997;273:H12–H18.
26. Lowry OH, Lopez JA. The determination of inorganic phosphate in the presence
of labile phosphate esters. J Biol Chem. 1946;162:421–428.
27. Gupta RC, Mishra S, Yang XP, Sabbah HN. Reduced inhibitor 1 and 2 activity is
associated with increased protein phosphatase type 1 activity in left
ventricular myocardium of one-kidney, one-clip hypertensive rats. Mol Cell
Biochem. 2005;269:49–57.
28. Mishra S, Gupta RC, Tiwari N, Sharov VG, Sabbah HN. Molecular mechanisms
of reduced sarcoplasmic reticulum Ca(2+) uptake in human failing left
ventricular myocardium. J Heart Lung Transplant. 2002;21:366–373.
29. Gupta RC, Mishra S, Mishima T, Goldstein S, Sabbah HN. Reduced
sarcoplasmic reticulum Ca(2+)-uptake and expression of phospholamban in
left ventricular myocardium of dogs with heart failure. J Mol Cell Cardiol.
1999;31:1381–1389.
30. Bolte S, Cordelieres FP. A guided tour into subcellular colocalization analysis in
light microscopy. J Microsc. 2006;224:213–232.
31. Fernandez-Sanz C, Ruiz-Meana M, Miro-Casas E, Nunez E, Castellano J,
Loureiro M, Barba I, Poncelas M, Rodriguez-Sinovas A, Vazquez J, Garcia-
Dorado D. Defective sarcoplasmic reticulum-mitochondria calcium exchange
in aged mouse myocardium. Cell Death Dis. 2014;5:e1573.
32. Eirin A, Zhu XY, Ferguson CM, Riester SM, van Wijnen AJ, Lerman A, Lerman
LO. Intra-renal delivery of mesenchymal stem cells attenuates myocardial
injury after reversal of hypertension in porcine renovascular disease. Stem Cell
Res Ther. 2015;6:7.
33. Zhang X, Li ZL, Crane JA, Jordan KL, Pawar AS, Textor SC, Lerman A, Lerman
LO. Valsartan regulates myocardial autophagy and mitochondrial turnover in
experimental hypertension. Hypertension. 2014;64:87–93.
34. Palacios R, Merchante N, Macias J, Gonzalez M, Castillo J, Ruiz J, Marquez M,
Gomez-Mateos J, Pineda JA, Santos J. Incidence of and risk factors for insulin
resistance in treatment-naive HIV-infected patients 48 weeks after starting
highly active antiretroviral therapy. Antivir Ther. 2006;11:529–535.
35. Ta NL, Jia X, Kiebish M, Seyfried TN. Autosomal dominant inheritance of brain
cardiolipin fatty acid abnormality in VM/DK mice: association with hypoxic-
induced cognitive insensitivity. Lipids. 2014;49:113–117.
36. Valianpour F, Wanders RJA, Barth PG, Overmars H, van Gennip AH.
Quantitative and compositional study of cardiolipin in platelets by electrospray
ionization mass spectrometry: application for the identification of barth
syndrome patients. Clin Chem. 2002;48:1390–1397.
37. Wilson SH, Simari RD, Best PJ, Peterson TE, Lerman LO, Aviram M, Nath KA,
Holmes DR Jr, Lerman A. Simvastatin preserves coronary endothelial function
in hypercholesterolemia in the absence of lipid lowering. Arterioscler Thromb
Vasc Biol. 2001;21:122–128.
38. Wilson SH, Best PJ, Lerman LO, Holmes DR Jr, Richardson DM, Lerman A.
Enhanced coronary vasoconstriction to oxidative stress product, 8-epi-
prostaglandinf2 alpha, in experimental hypercholesterolemia. Cardiovasc
Res. 1999;44:601–607.
39. Herrmann J, Lerman LO, Rodriguez-Porcel M, Holmes DR Jr, Richardson DM,
Ritman EL, Lerman A. Coronary vasa vasorum neovascularization precedes
epicardial endothelial dysfunction in experimental hypercholesterolemia.
Cardiovasc Res. 2001;51:762–766.
40. Aly A, Peterson K, Lerman A, Lerman L, Rodriguez-Porcel M. Role of oxidative
stress in hypoxia preconditioning of cells transplanted to the myocardium: a
molecular imaging study. J Cardiovasc Surg (Torino). 2011;52:579–585.
41. Zhao K, Luo G, Giannelli S, Szeto HH. Mitochondria-targeted peptide
prevents mitochondrial depolarization and apoptosis induced by tert-butyl
hydroperoxide in neuronal cell lines. Biochem Pharmacol. 2005;70:1796–
1806.
42. Aravamudan B, Kiel A, Freeman M, Delmotte P, Thompson M, Vassallo R, Sieck
GC, Pabelick CM, Prakash YS. Cigarette smoke-induced mitochondrial
fragmentation and dysfunction in human airway smooth muscle. Am J Physiol
Lung Cell Mol Physiol. 2014;306:L840–L854.
DOI: 10.1161/JAHA.115.003118 Journal of the American Heart Association 18
Mitochondria in Cardiac Dysfunction Eirin et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
43. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease
and the risks of death, cardiovascular events, and hospitalization. N Engl J
Med. 2004;351:1296–1305.
44. Edwards MS, Craven TE, Burke GL, Dean RH, Hansen KJ. Renovascular disease
and the risk of adverse coronary events in the elderly: a prospective,
population-based study. Arch Intern Med. 2005;165:207–213.
45. Wright JR, Shurrab AE, Cooper A, Kalra PR, Foley RN, Kalra PA. Progression of
cardiac dysfunction in patients with atherosclerotic renovascular disease.
QJM. 2009;102:695–704.
46. Goffart S, von Kleist-Retzow JC, Wiesner RJ. Regulation of mitochondrial
proliferation in the heart: power-plant failure contributes to cardiac failure in
hypertrophy. Cardiovasc Res. 2004;64:198–207.
47. Szewczyk A, Jarmuszkiewicz W, Koziel A, Sobieraj I, Nobik W, Lukasiak A, Skup
A, Bednarczyk P, Drabarek B, Dymkowska D, Wrzosek A, Zablocki K.
Mitochondrial mechanisms of endothelial dysfunction. Pharmacol Rep.
2015;67:704–710.
48. Li J, Romestaing C, Han X, Li Y, Hao X, Wu Y, Sun C, Liu X, Jefferson LS, Xiong J,
Lanoue KF, Chang Z, Lynch CJ, Wang H, Shi Y. Cardiolipin remodeling by alcat1
links oxidative stress and mitochondrial dysfunction to obesity. Cell Metab.
2010;12:154–165.
49. Sakamoto T, Inoue T, Otomo Y, Yokomori N, Ohno M, Arai H, Nakagawa Y.
Deficiency of cardiolipin synthase causes abnormal mitochondrial function and
morphology in germ cells of caenorhabditis elegans. J Biol Chem.
2012;287:4590–4601.
50. Moulin M, Solgadi A, Veksler V, Garnier A, Ventura-Clapier R, Chaminade P.
Sex-specific cardiac cardiolipin remodelling after doxorubicin treatment. Biol
Sex Differ. 2015;6:20.
51. Sparagna GC, Johnson CA, McCune SA, Moore RL, Murphy RC. Quantitation of
cardiolipin molecular species in spontaneously hypertensive heart failure rats
using electrospray ionization mass spectrometry. J Lipid Res. 2005;46:1196–
1204.
52. Puigserver P, Wu Z, Park CW, Graves R, Wright M, Spiegelman BM. A cold-
inducible coactivator of nuclear receptors linked to adaptive thermogenesis.
Cell. 1998;92:829–839.
53. Virbasius JV, Scarpulla RC. Activation of the human mitochondrial transcription
factor a gene by nuclear respiratory factors: a potential regulatory link
between nuclear and mitochondrial gene expression in organelle biogenesis.
Proc Natl Acad Sci USA. 1994;91:1309–1313.
54. Janumyan YM, Sansam CG, Chattopadhyay A, Cheng N, Soucie EL, Penn LZ,
Andrews D, Knudson CM, Yang E. Bcl-xL/Bcl-2 coordinately regulates
apoptosis, cell cycle arrest and cell cycle entry. EMBO J. 2003;22:5459–5470.
55. Jastroch M, Divakaruni AS, Mookerjee S, Treberg JR, Brand MD. Mitochondrial
proton and electron leaks. Essays Biochem. 2010;47:53–67.
56. Franzini-Armstrong C. Er-mitochondria communication. How privileged? Phys-
iology (Bethesda). 2007;22:261–268.
57. Kohlhaas M, Maack C. Adverse bioenergetic consequences of Na+-Ca2+
exchanger-mediated Ca2+ influx in cardiac myocytes. Circulation.
2010;122:2273–2280.
58. Dunn KW, Kamocka MM, McDonald JH. A practical guide to evaluating
colocalization in biological microscopy. Am J Physiol Cell Physiol. 2011;300:
C723–C742.
59. Marks AR. Calcium cycling proteins and heart failure: mechanisms and
therapeutics. J Clin Invest. 2013;123:46–52.
60. Demaurex N, Poburko D, Frieden M. Regulation of plasma membrane calcium
fluxes by mitochondria. Biochem Biophys Acta. 2009;1787:1383–1394.
61. De Marchi U, Castelbou C, Demaurex N. Uncoupling protein 3 (UCP3)
modulates the activity of sarco/endoplasmic reticulum Ca2+-atpase (SERCA)
by decreasing mitochondrial ATP production. J Biol Chem. 2011;286:32533–
32541.
62. Lugus JJ, Ngoh GA, Bachschmid MM, Walsh K. Mitofusins are required for
angiogenic function and modulate different signaling pathways in cultured
endothelial cells. J Mol Cell Cardiol. 2011;51:885–893.
63. Csiszar A, Labinskyy N, Pinto JT, Ballabh P, Zhang H, Losonczy G, Pearson K, de
Cabo R, Pacher P, Zhang C, Ungvari Z. Resveratrol induces mitochondrial
biogenesis in endothelial cells. Am J Physiol Heart Circ Physiol. 2009;297:H13–
H20.
64. Pangare M, Makino A. Mitochondrial function in vascular endothelial cell in
diabetes. J Smooth Muscle Res. 2012;48:1–26.
65. Zhu XY, Daghini E, Chade AR, Rodriguez-Porcel M, Napoli C, Lerman A, Lerman
LO. Role of oxidative stress in remodeling of the myocardial microcirculation in
hypertension. Arterioscler Thromb Vac Biol. 2006;26:1746–1752.
66. Arany Z, Foo SY, Ma Y, Ruas JL, Bommi-Reddy A, Girnun G, Cooper M, Laznik D,
Chinsomboon J, Rangwala SM, Baek KH, Rosenzweig A, Spiegelman BM. HIF-
independent regulation of VEGF and angiogenesis by the transcriptional
coactivator PGC-1alpha. Nature. 2008;451:1008–1012.
67. Kluge MA, Fetterman JL, Vita JA. Mitochondria and endothelial function. Circ
Res. 2013;112:1171–1188.
68. Xu MJ, Song P, Shirwany N, Liang B, Xing J, Viollet B, Wang X, Zhu Y, Zou MH.
Impaired expression of uncoupling protein 2 causes defective postischemic
angiogenesis in mice deficient in AMP-activated protein kinase alpha subunits.
Arterioscler Thromb Vac Biol. 2011;31:1757–1765.
69. Dai DF, Johnson SC, Villarin JJ, Chin MT, Nieves-Cintron M, Chen T, Marcinek
DJ, Dorn GW II, Kang YJ, Prolla TA, Santana LF, Rabinovitch PS. Mitochondrial
oxidative stress mediates angiotensin II-induced cardiac hypertrophy and
Galphaq overexpression-induced heart failure. Circ Res. 2011;108:837–846.
70. Siwik DA, Pagano PJ, Colucci WS. Oxidative stress regulates collagen synthesis
and matrix metalloproteinase activity in cardiac fibroblasts. Am J Physiol Cell
Physiol. 2001;280:C53–C60.
71. Joshi M, Kotha SR, Malireddy S, Selvaraju V, Satoskar AR, Palesty A, McFadden
DW, Parinandi NL, Maulik N. Conundrum of pathogenesis of diabetic
cardiomyopathy: role of vascular endothelial dysfunction, reactive oxygen
species, and mitochondria. Mol Cell Biochem. 2014;386:233–249.
72. Kuwahara F, Kai H, Tokuda K, Kai M, Takeshita A, Egashira K, Imaizumi T.
Transforming growth factor-beta function blocking prevents myocardial
fibrosis and diastolic dysfunction in pressure-overloaded rats. Circulation.
2002;106:130–135.
73. Lopez B, Gonzalez A, Diez J. Role of matrix metalloproteinases in hypertension-
associated cardiac fibrosis. Curr Opin Nephrol Hypertens. 2004;13:197–204.
74. Jacobson J, Duchen MR, Heales SJ. Intracellular distribution of the fluorescent
dye nonyl acridine orange responds to the mitochondrial membrane potential:
implications for assays of cardiolipin and mitochondrial mass. J Neurochem.
2002;82:224–233.
DOI: 10.1161/JAHA.115.003118 Journal of the American Heart Association 19
Mitochondria in Cardiac Dysfunction Eirin et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
